Bifidobacterium Infantis for Bloating Relief

Research suggests that Bifidobacterium infantis 35624 may help reduce bloating in people with irritable bowel syndrome, based on two randomized controlled trials and a broader review of clinical evidence — with a 2006 RCT finding statistically significant reductions in bloating at a specific dose among IBS patients, and a 2011 review identifying this strain as one of a limited number of treatments showing meaningful benefit for bloating in functional gastrointestinal disorders. However, the evidence is not uniformly positive: a 2017 RCT found no significant difference between the probiotic and placebo in adults from the general population who had not sought medical care, with researchers attributing this to a strong placebo response and milder baseline symptoms in that group. Studies indicate that the benefits observed may be specific to clinical IBS populations rather than people with mild or subclinical bloating, and the 2011 review also noted that bloating is rarely the primary focus of trials in this area, limiting the strength of conclusions that can be drawn. Overall, the existing research points to some promise for this strain in IBS-related bloating, but the mixed findings across populations and study designs suggest the picture is more nuanced than a straightforward endorsement.